Ali Deniz

Ali Deniz

Auto-generated profile, based on publicly available information

Ali Deniz

Cukurova Universitesi

Research Focus & Metrics

Academic Career Length

20Years (2007-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
25 October 2010 in Journal of Interventional Cardiology
Verified
Journal Article
Closed access
PDF file
AOAli Oto
Ali Oto
KAKudret Aytemir
Kudret Aytemir
SOSercan Okutucu
Sercan Okutucu
EKERGUN BARIS KAYA
ERGUN BARIS KAYA
ADAli Deniz
Ali Deniz
GKGiray Kabakci
Giray Kabakci

24 May 2007 in Catheterization and Cardiovascular Interventions
Verified
Journal Article
Closed access
PDF file
AOAli Oto
Ali Oto
KAKudret Aytemir
Kudret Aytemir
ADAli Deniz
Ali Deniz

15 July 2020 in Acta Cardiologica
Verified
Journal Article
Closed access
ÇÖÇağlar Özmen
Çağlar Özmen
ODOnur Sinan Deveci
Onur Sinan Deveci
ÖTÖmer Tepe
Ömer Tepe
CYCuma Yesildas
Cuma Yesildas
İÜİlker Ünal
İlker Ünal
AUAyhan Usal
Ayhan Usal
Background In heart failure (HF), various biomarkers have been established for prognosis. However, little is known about the relevance of copeptin measurements to HF. This study aimed to explore the prognostic value of copeptin for predicting cardiovascular (CV) death or HF-related re-hospitalisation in patients with acute decompensated HF. Materials and Methods We prospectively enrolled 155 consecutive patients with acute signs and symptoms of HF. Plasma copeptin and N-terminal pro-B-type natriuretic peptide (NT-proBNP) levels were measured at admission. Patients were monitored for 90 days regarding the composite endpoint of CV death or acute HF-related re-hospitalisation. Results Of the 155 patients enrolled, 40 reached the endpoint, and 115 were in a stable condition during follow-up. Patients who reached an adverse endpoint showed higher NT-proBNP and copeptin levels compared to patients in stable condition. Receiver operating characteristic curve analysis revealed that the area under curve of copeptin 0.844 (95% CI, 0.753-0.935) was superior to that of NT-proBNP 0.809 (95% CI, 0.729-0.890) for the prediction of adverse events within 90 days. Meanwhile, compared to the group with lower copeptin levels (= 34 pmol/L) were at a 10.672-times higher risk of CV death or acute HF-related re-hospitalisation. Multivariate Cox proportional hazards regression analysis revealed that increased copeptin level was a significantly independent predictor of adverse events (risk ratio, 1.051; 95% CI, 1.020-1.083;p < 0.001). Conclusion Copeptin was found to be a strong, novel marker for predicting CV death or HF-related re-hospitalisation in patients with acute decompensated HF.

1 January 2016 in International Heart Journal
Verified
Journal Article
Open access
ÇÖÇağlar Özmen
Çağlar Özmen
ADAli Deniz
Ali Deniz
RARabia Eker Akilli
Rabia Eker Akilli
ODOnur Sinan Deveci
Onur Sinan Deveci
CCCaglar Emre Cagliyan
Caglar Emre Cagliyan
MKMehmet Kanadasi
Mehmet Kanadasi
Pulmonary embolism (PE) is a potentially life-threatening condition and the fact that 90% of PE originate from lower limb veins highlights the significance of early detection and treatment of deep vein thrombosis. Massive/high risk PE involving circulatory collapse or systemic arterial hypotension is associated with an early mortality rate of approximately 50%, in part from right ventricular (RV) failure. Intermediate risk/submassive PE, on the other hand, is defined as PE-related RV dysfunction, troponin and/or B-type natriuretic peptide elevation despite normal arterial pressure. Without prompt treatment, patients with intermediate risk PE may progress to the massive category with a potentially fatal outcome. In patients with PE and right ventricular dysfunction (RVD), in hospital mortality ranges from 5% to 17%, significantly higher than in patients without RVD.

1 December 2020 in Revista da Associação Médica Brasileira
Verified
Journal Article
Open access
PDF file
ÇÖÇağlar Özmen
Çağlar Özmen
ODOnur Sinan Deveci
Onur Sinan Deveci
MKMuhammet Bugra Karaaslan
Muhammet Bugra Karaaslan
OTOya Baydar Toprak
Oya Baydar Toprak
AAAnıl Akray
Anıl Akray
AUAyhan Usal
Ayhan Usal
SUMMARY OBJECTIVE: Early diagnosis and risk stratification may provide a better prognosis in pulmonary embolism (PE). Copeptin has emerged as a valuable predictive biomarker in various cardiovascular diseases. The aim of this study was to determine the levels of copeptin in patients with acute PE and to evaluate its relationship with disease severity and PE-related death. METHODS: Fifty-four patients and 60 healthy individuals were included in this study. Copeptin concentrations and right ventricular dysfunction were analyzed. The correlation between copeptin levels and hemodynamic and echocardiographic parameters was examined. After these first measurements, patients were evaluated with PE-related mortality at the one-year follow-up. RESULTS: The copeptin levels were higher in PE patients than in the control group (8.3 ng/mL vs 3.8 ng/mL, p<0.001). Copeptin levels were found to be significantly higher in patients with PE-related death and right ventricular dysfunction (10.2 vs 7.5 ng/ml, p=0.001; 10.5 vs 7.5 ng/ml, p=0.002, respectively). When the cut-off value of copeptin was ≥5.85, its sensitivity and specificity for predicting PE were 71.9% and 85.0%, respectively (AUC=0.762, 95% CI=0.635-0.889, p<0.001). CONCLUSIONS: The copeptin measurement had moderate sensitivity and specificity in predicting the diagnosis of PE, and the copeptin level was significantly higher in patients with PE-related death at the one-year follow-up. Copeptin may be a useful new biomarker in predicting diagnosis, risk stratification, and prognosis of PE.

13 April 2023 in European Journal of Medical Genetics
Verified
Journal Article
Closed access
FBFatma Derya Bulut
Fatma Derya Bulut
DKDeniz Kor
Deniz Kor
SKSebile Kılavuz
Sebile Kılavuz
Berna Seker YilmazBerna Seker Yilmaz
Berna Seker Yilmaz
IKİrEm Kaplan
İrEm Kaplan
NMNeslihan Onenli Mungan
Neslihan Onenli Mungan